Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B‐containing lipoproteins

Abstract. This study examined the actions of pravastatin on the metabolism of apolipoprotein B (apo B) in very low‐, intermediate‐, and low‐density lipoproteins (VLDL, IDL, and LDL) in 10 patients with primary moderate hypercholesterolaemia. 131I‐VLDL apo B was used as a tracer, and appearance of label was followed into IDL apo B and LDL apo B. Compared to placebo, pravastatin therapy reduced levels of cholesterol in total plasma, LDL, VLDL, and IDL cholesterol by 25%, 29%, 31%, and 47%, respectively. Pravastatin treatment also significantly decreased concentrations of apo B in LDL, IDL, and VLDL. The drug significantly reduced the mean production rate for VLDL apo B by 40%, and decreased production rates for LDL apo B in eight of 10 patients. In contrast, fractional catabolic rates (FCRs) were not altered significantly in any of the three lipoprotein fractions on pravastatin therapy. Further, pravastatin produced no consistent changes in LDL particle size, composition, or LDL subclass pattern. Thus pravastatin seemingly reduced input rates for all apo B‐containing lipoproteins. Consistent with previous studies, this response was most likely the result of enhanced removal of nascent lipoproteins by increased activity of LDL receptors, although decreased synthesis of apo B in the liver is a possible second action.

[1]  S M Grundy,et al.  Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Rudel,et al.  Metabolic behavior of hepatic VLDL and plasma LDL apoB-100 in African green monkeys. , 1989, Journal of lipid research.

[3]  M. King,et al.  Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. , 1988, American journal of human genetics.

[4]  S. Grundy,et al.  Comparison of a high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. , 1988, The New England journal of medicine.

[5]  S. Grundy,et al.  Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. , 1988, The Journal of pediatrics.

[6]  S. Grundy.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. , 1988, The New England journal of medicine.

[7]  S. Grundy,et al.  Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. , 1988, Kidney international.

[8]  S. Grundy,et al.  Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. , 1988, Atherosclerosis.

[9]  S. Grundy,et al.  Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. , 1988, The New England journal of medicine.

[10]  R. Desnick,et al.  Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. , 1987, The Journal of clinical investigation.

[11]  R. Lees,et al.  Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. , 1987, Annals of internal medicine.

[12]  R. Krauss,et al.  INTERMEDIATE-DENSITY LIPOPROTEINS AND PROGRESSION OF CORONARY ARTERY DISEASE IN HYPERCHOLESTEROLAEMIC MEN , 1987, The Lancet.

[13]  S. Grundy,et al.  Increased catabolism of VLDL-apolipoprotein B and synthesis of bile acids in a case of hypobetalipoproteinemia. , 1987, Metabolism: clinical and experimental.

[14]  R. Krauss,et al.  Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. , 1987, American heart journal.

[15]  T. Südhof,et al.  Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Stalenhoef,et al.  EFFECTS OF SYNVINOLIN (MK-733) ON PLASMA LIPIDS IN FAMILIAL HYPERCHOLESTEROLAEMIA , 1986, The Lancet.

[17]  S. Grundy,et al.  Kinetic Heterogeneity of Low Density Lipoproteins in Primary Hypertriglyceridemia , 1986, Arteriosclerosis.

[18]  W. F. Hoffman,et al.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. , 1986, Journal of medicinal chemistry.

[19]  K. Bailey,et al.  Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. , 1986, The American journal of cardiology.

[20]  S. Grundy,et al.  Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin. , 1986, Metabolism: clinical and experimental.

[21]  S. Grundy,et al.  Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. , 1985, Journal of lipid research.

[22]  S. Grundy,et al.  Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease. , 1985, The Journal of clinical investigation.

[23]  B V Howard,et al.  Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, intermediate density lipoproteins, and low density lipoproteins. , 1985, The Journal of clinical investigation.

[24]  S. Grundy,et al.  Influence of obesity on the metabolism of apolipoprotein B in humans. , 1985, The Journal of clinical investigation.

[25]  P. Nestel,et al.  Lipoprotein predictors of the severity of coronary artery disease in men and women. , 1985, Circulation.

[26]  D. Illingworth,et al.  Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. , 1984, The Journal of clinical investigation.

[27]  A. Kissebah,et al.  Low Density Lipoprotein Metabolism in Familial Combined Hyperlipidemia: Mechanism of the Multiple Lipoprotein Phenotypic Expression , 1984, Arteriosclerosis.

[28]  Y. Matsuzawa,et al.  Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. , 1984, Atherosclerosis.

[29]  M. Brown,et al.  Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. , 1983, The Journal of clinical investigation.

[30]  S. Grundy,et al.  Influence of polyunsaturated fats on composition of plasma lipoproteins and apolipoproteins. , 1982, Journal of lipid research.

[31]  H. Mabuchi,et al.  Intermediate‐density Lipoprotein and Cholesterol‐rich Very Low Density Lipoprotein in Angiographically Determined Coronary Artery Disease , 1981, Circulation.

[32]  R. Mahley,et al.  Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. , 1981, The Journal of biological chemistry.

[33]  A. Kissebah,et al.  Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. , 1981, Metabolism: clinical and experimental.

[34]  D. Bilheimer,et al.  Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R Monaghan,et al.  Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Endo,et al.  Therapeutic effects of ML-236B in primary hypercholesterolemia. , 1980, Atherosclerosis.

[37]  R. Mahley,et al.  Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. , 1979, Biochimica et biophysica acta.

[38]  S. Grundy,et al.  Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects. , 1979, The Journal of clinical investigation.

[39]  G. Schonfeld,et al.  Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins. , 1979, Metabolism: clinical and experimental.

[40]  Y. Tsujita,et al.  Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1979, Atherosclerosis.

[41]  Y. Tsujita,et al.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. , 1976, The Journal of antibiotics.

[42]  P. Tarbutton,et al.  Enzymatic Determination of Total Cholesterol in Serum , 1974 .

[43]  E. Bernt,et al.  Enzymatic determination of total cholesterol in serum. , 1974, Zeitschrift fur klinische Chemie und klinische Biochemie.

[44]  D. Bilheimer,et al.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. , 1972, Biochimica et biophysica acta.

[45]  A. Mcfarlane,et al.  Efficient Trace-labelling of Proteins with Iodine , 1958, Nature.

[46]  C. Matthews,et al.  The theory of tracer experiments with 131I-labelled plasma proteins. , 1957, Physics in medicine and biology.

[47]  J. Hewitt,et al.  The role of lipids and lipoproteins in atherosclerosis. , 1950, Science.

[48]  W. Clark.  Leonor Michaelis: 1875-1949. , 1950, Science.

[49]  Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II. , 1986, JAMA.

[50]  S. Young,et al.  Cholestyramine-induced changes in low density lipoprotein composition and metabolism. I. Studies in the guinea pig. , 1985, Journal of lipid research.

[51]  S. Grundy,et al.  Low density lipoprotein metabolism in hypertriglyceridemic and normolipidemic patients with coronary heart disease. , 1985, Journal of lipid research.

[52]  M. Brown,et al.  The LDL receptor locus and the genetics of familial hypercholesterolemia. , 1979, Annual review of genetics.